维普期刊资源整合服务平台（V6.5）

40篇 您的检索式：作者名="PAPADIMITRAKOPOULOU V"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Non-small cell lung cancer beyond biomarkers:the evolving landscape of clinical trial design显示文摘	Dimou A Papadimitrakopoulou V	2014	J Pers Med2014，4，3：	1
2	DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma显示文摘	Kim S K Fan Y Papadimitrakopoulou V	1996	Cancer Res1996，56，11：	1
3	A phaseⅡstudy ofRAD001(R)(everolimus)monotherapy in patients(pts)with ad-vanced non-small cell lung cancer(NSCLC)failing prior platinum-based chemotherapy(C)or prior C and EGFR inhibitors(EGFR-I)显示文摘	Papadimitrakopoulou V Soria J Douillard J	2007	Journal of Clinical Oncology2007，25，：	1
4	Pembroli- zumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C显示文摘	Papadimitrakopoulou V Patnaik A Borghaei H	2015	j Clin Oncol2015，，：	1
5	Immunotherapy in lung cancer显示文摘	Massarelli E Papadimitrakopoulou V Welsh J	2014	Transl Lung Cancer Res2014，3，1：	1
6	Development of PI3K/Akt/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer显示文摘	Papadimitrakopoulou V	2012	J Thoracic On- col2012，7，8：	1
7	Development of PI3K/AKT/mTOR pathwayinhibitors and their application in personalized therapy for non-small-cell lung cancer显示文摘	Papadimitrakopoulou V	2012	J Thorac Oncol2012，7，8：	1
8	The Akt/mTOR and mitogen-activated protein kinasepathways in lung cancer therapy 显示文摘	Papadimitrakopoulou V Adjei AA	2006	J Thorac Oncol2006，1，7：	1
9	Phase II trial of the histone deacetylase in- hibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or meta- static head and neck cancer显示文摘	Blumenschein G R Jr Kies M S Papadimitrakopoulou V A	2008	Invest New Drugs2008，26，：	1
10	DPC4,a candidate tumor suppressor gene,is altered infrequently in head and neck squamous cell carcinoma显示文摘	Kim SK Fan Y Papadimitrakopoulou V	1996	Cancer Res1996，56，11：	1
11	Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non- small-cell lung cancer显示文摘	Papadimitrakopoulou V	2012	J Thorac Oncol2012，7，：	1
12	Cyclin D1and cancer development in laryngeal premalignancy patients显示文摘	PAPADIMITRAKOPOULOU V IZZO J G LIU D D	2009	Cancer Prev Res(Phila)2009，2，：	1
13	Development of PI3K/AKT/ mTOR pathway inhibitors and their application in per- sonalized therapy for non-small-cell lung cancer显示文摘	Papadimitrakopoulou V	2012	J Thorac Oncol2012，7，8：	1
14	DPC4, a candidate tumor suppression gene, is altered infrequently in head and neck squamous cell carcinoma显示文摘	Kim SK Fan Y Papadimitrakopoulou V	1996	Cancer Res1996，56，11：	1
15	The Akt/mTOR and mitogen- activated protein kinase pathways in lung cancer therapy显示文摘	Papadimitrakopoulou V Adjei A A	2006	J Thora~c 0ncol2006，1，7：	1
16	Non-small cell lung cancerbeyond biomarkers : the evolving landscape of clinical trialdesign显示文摘	DIMOU A PAPADIMITRAKOPOULOU V	2014	J Pers Med2014，4，3：	1
17	Development of PI3K/AKT/mTOR path- way inhibitors and their application in personNized therapy for non-small-cell lung cancer显示文摘	Papadimitrakopoulou V	2012	J Thorac Oncol2012，7，8：	1
18	Cyclin D1and cancer development in laryngeal premalignancy patients显示文摘	Papadimitrakopoulou V Lzzo JG Liu DD	2009	Cancer Prev Res2009，2，1：	1
19	Pembroli- zumab ( pembro ; MK-3475 ) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer(NSCLC) : KEYNOTE-021 Cohorts A and C 显示文摘	Papadimitrakopoulou V Patnaik A Borghaei H	2015	J Clin Oncol2015，，：	1
20	Cyclin D1 and cancer development in laryngeal premalignancy patients显示文摘	PAPADIMITRAKOPOULOU V IZZO J G LIU D D	2009	Cancer Prev Res (Phila Pa)2009，2，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示